MAP2K7 and cholangiocarcinoma: A phase II trial of atezolizumab (anti-PD-L1 antibody) with or without the MEK inhibitor cobimetinib in CCA patients demonstrated improved PFS with the combination (3.65 vs. 1.87 months).